NCT05623501View on ClinicalTrials.gov

Phase I, Dose-Escalation Study of Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 15, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Alcohol-Related Disorders
Interventions
DRUG

Dihydromyricetin

Dose-escalation and lysine preparation

Trial Locations (1)

90089

University of Southern California, Los Angeles

All Listed Sponsors
lead

University of Southern California

OTHER

NCT05623501 - Phase I, Dose-Escalation Study of Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease | Biotech Hunter | Biotech Hunter